Praxis Shares Rise on Ulixacaltamide Breakthrough Designation
By Colin Kellaher
Shares of Praxis Precision Medicines rose sharply on Monday after the clinical-stage biopharmaceutical company won a key U.S. Food and Drug Administration designation for its drug candidate for essential tremor.
Praxis on Monday said the FDA granted breakthrough-therapy designation to ulixacaltamide for people with the nervous-system condition that causes rhythmic shaking that they can't control.
Analysts at Truist, who have a buy rating and $500 price target on Praxis shares, said the designation is incrementally positive and derisking for the Boston company's essential-tremor program.
The FDA's breakthrough-therapy designation aims to expedite the development and review of a drug for serious conditions when preliminary clinical evidence shows the drug might offer substantial improvement over available therapies.
Praxis said it is on track for filing for FDA approval of ulixacaltamide in early 2026.
Praxis shares were recently changing hands at $300.74, up nearly 13%.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 29, 2025 10:57 ET (15:57 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States